ArticleBlood2022
Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock.
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Vesicles for cell crosstalk in bone: composition, function and application.Science China. Life sciences · 2026Review
- Disulfiram as an anti-inflammatory agent: mechanisms, nano-delivery strategies, and applications in non-oncologic diseases.RSC advances · 2025Review
- Pattern recognition receptor-associated immuno-thrombotic transcript changes in platelets and leukocytes with COVID19.PLoS pathogens · 2025Article
- The Procoagulant and Fibrinolytic Balance of Extracellular Vesicles Predicts Mortality in Septic Shock Patients.Journal of extracellular vesicles · 2025Article
- Pathogenic and therapeutic roles of extracellular vesicles in sepsis.Frontiers in immunology · 2025Review
- Combatting sepsis-induced myocardial dysfunction: emerging mechanisms and immunomodulatory breakthroughs.Frontiers in immunology · 2025Review
- Role of COX6C and NDUFB3 in septic shock and stroke.Open medicine (Warsaw, Poland) · 2024Article
- Nanolevel Immunomodulators in Sepsis: Novel Roles, Current Perspectives, and Future Directions.International journal of nanomedicine · 2024Review
- Pyroptotic Macrophage-Derived Microvesicles Accelerate Formation of Neutrophil Extracellular TrapsInternational journal of biological sciences · 2024Article
- Crosstalk between the plasminogen/plasmin system and inflammation resolution.Journal of thrombosis and haemostasis : JTH · 2023Review
- Plasminogen System in the Pathophysiology of Sepsis: Upcoming Biomarkers.International journal of molecular sciences · 2023Review
- Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis.Thrombosis and haemostasis · 2023Article
- Plasmin and plasminogen prevent sepsis severity by reducing neutrophil extracellular traps and systemic inflammation.JCI insight · 2023Article
- How Extracellular Nano-Vesicles Can Play a Role in Sepsis? An Evidence-Based Review of the Literature.International journal of nanomedicine · 2023Review
- Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.Biomolecules · 2022Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microvesicles (MVs) have previously been shown to exert profibrinolytic capacity, which is increased in patients with septic shock (SS) with a favorable outcome. We, therefore, hypothesized that the plasmin generation capacity (PGC) could confer to MVs a protective effect supported by their capacity to lyse a thrombus, and we investigated the mechanisms involved. Using an MV-PGC kinetic assay, ELISA, and flow cytometry, we found that granulocyte MVs (Gran-MVs) from SS patients display a heterogeneous PGC profile driven by the uPA (urokinase)/uPAR system. In vitro, these MVs lyse a thrombus according to their MV-PGC levels in a uPA/uPAR-dependent manner, as shown in a fluorescent clot lysis test and a lysis front retraction assay. Fibrinolytic activators conveyed by MVs contribute to approximately 30% of the plasma plasminogenolytic capacity of SS patients. In a murine model of SS, the injection of high PGC Gran-MVs significantly improved mouse survival and reduced the number of thrombi in vital organs. This was associated with a modification of the mouse coagulation and fibrinolysis properties toward a more fibrinolytic profile. Interestingly, mouse survival was not improved when soluble uPA was injected. Finally, using a multiplex array on plasma from SS patients, we found that neutrophil elastase correlates with the effect of high-PGC-capacity plasma and modulates the Gran-MV plasmin generation capacity by cleaving uPA-PAI-1 complexes. In conclusion, we show that the high PGC level displayed by Gran-MVs reduces thrombus formation and improves survival, conferring to Gran-MVs a protective role in a murine model of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.